Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Metabolic marker group for diagnosing coronary heart disease

A metabolic marker, coronary heart disease technology, applied in the field of biochemistry, to improve the convenience of diagnosis, accurate and reliable results, and promote standardization

Active Publication Date: 2016-07-13
苏州帕诺米克生物科技有限公司
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No one has used plasma metabolite levels to diagnose coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolic marker group for diagnosing coronary heart disease
  • Metabolic marker group for diagnosing coronary heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Screening and characterization of plasma differential metabolites between patients with coronary heart disease and patients without coronary heart disease (including normal coronary arteries and patients with coronary atherosclerosis)

[0027] 1. Objects and methods

[0028] 1. The source of the specimen

[0029] After obtaining the consent of the patients, the peripheral venous blood plasma of 480 patients with coronary atherosclerosis, 867 patients with coronary heart disease and 350 patients with normal coronary arteries in Jiangsu Provincial People's Hospital from September 2010 to June 2015 were collected. Normal coronary arteries were confirmed by coronary angiography. The age and sex of normal coronary artery patients were matched with patients with coronary atherosclerosis and coronary heart disease. All patients with coronary atherosclerosis, coronary heart disease and normal coronary arteries have normal heart, lung, liver, kidney and hematopoieti...

Embodiment 2

[0053] Example 2: Construction of ROC curves to compare the ability of 6 differential metabolites to diagnose patients with coronary heart disease and non-coronary heart disease (including normal coronary arteries and coronary atherosclerosis)

[0054] Receiver operating curve (ROC) method was used for verification, and the expression levels of differential metabolites in the plasma of patients with coronary heart disease and non-coronary heart disease (including normal coronary arteries and coronary atherosclerosis) were used to judge its use in the diagnosis of coronary heart disease Ability. The results showed that six differential metabolites, citramalic acid, methionine, taurine, malic acid, phenylalanine, and linoleic acid, were used individually to diagnose and distinguish patients with coronary heart disease from those with normal coronary arteries and those with coronary heart disease. The ability to compare with patients with coronary atherosclerosis is strong, and t...

Embodiment 3

[0070] Embodiment 3: application in the screening treatment or the medicine of alleviating coronary heart disease

[0071] The blood plasma of 185 patients with coronary heart disease before and after the drug treatment was detected, and the results showed that: with the increase of the course of drug treatment, the patient's condition was gradually relieved, and the levels of the 6 metabolic markers provided by the present invention in the plasma gradually tended to It is at the level of normal coronary arteries, and there is no significant difference (P>0.05) between the plasma levels of normal coronary arteries after complete cure. This result is consistent with the detection results of coronary angiography. Therefore, the metabolic markers provided by the present invention can be used to screen drugs for treating or alleviating coronary heart disease.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a metabolic marker group for diagnosing a coronary heart disease. The metabolic marker group comprises one or more of citramalic acid, methionine, taurine, malic acid, phenylalanine and linoleic acid. In a ROC (receiver operating characteristic) curve evaluation method, under the condition that the AUC (area under curve) is larger than 0.5, the closer the AUC is to 1, the better the diagnosis effect is. A metabolic marker has lower accuracy when the AUC is 0.5-0.7, has certain accuracy when the AUC is 0.7-0.9 and has higher accuracy when the AUC is 0.9 or larger. Verification proves that when the single metabolic marker in the metabolic marker group is used for diagnosing and distinguishing patients with the coronary heart disease from subjects with normal coronary arteries, or diagnosing and distinguishing the patients with the coronary heart disease from patients with coronary atherosclerosis, the AUCs are all 0.7 or larger; when a plurality of the metabolic markers are used in combination, the AUC is closer to 1 than that when the single metabolic marker is used, so that the diagnosis effect is better; when six metabolic markers are used in combination, the AUC is closest to 1, and diagnosing and distinguishing effects are the best.

Description

technical field [0001] The invention belongs to the field of biochemistry and relates to disease diagnosis markers, in particular to a group of metabolic markers for diagnosing coronary heart disease. Background technique [0002] Coronary heart disease, also known as ischemic heart disease, involves atherosclerosis in the arteries supplying myocardial blood, that is, coronary atherosclerotic lesions cause vascular lumen narrowing or plaque formation or even rupture and complete blockage, resulting in myocardial ischemia and hypoxia. Or necrosis leads to cardiac ischemic disease, which leads to a series of serious cardiovascular events such as clinical angina pectoris and myocardial infarction. Coronary heart disease is the main killer of human health. It has the characteristics of high incidence rate, high disability rate, high recurrence rate, high mortality rate, and many complications. It has become a major disease that threatens the health of our people. [0003] Coron...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02
CPCG01N30/02G01N2800/323G01N2800/324
Inventor 齐炼文来茂德朱伟范勇
Owner 苏州帕诺米克生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products